Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30631057 | 1.00 | DPP4 (0.46) | DPP4GPR119KDM4EPKMALOX5AP | |
| SCHEMBL30631081 | 0.91 | GPR119 (0.44) | DPP4GPR119KDM4EPKMALOX5AP | |
| SCHEMBL25094741 | 0.91 | NAMPT (0.39) | DPP4GPR119ALOX5APFEN1 | |
| SCHEMBL26695713 | 0.91 | GPR119 (0.44) | DPP4GPR119KDM4EPKMALOX5AP | |
| SCHEMBL26610869 | 0.87 | DPP4 (0.39) | DPP4GPR119 | |
| SCHEMBL26610870 | 0.87 | DPP4 (0.39) | DPP4GPR119 | |
| SCHEMBL25094925 | 0.84 | GPR119 (0.44) | DPP4GPR119 | |
| SCHEMBL29898062 | 0.84 | GPR119 (0.44) | DPP4GPR119 | |
| SCHEMBL26696266 | 0.83 | NAMPT (0.41) | DPP4GPR119ALOX5APFEN1 | |
| SCHEMBL29898082 | 0.82 | ALOX5AP (0.34) | DPP4GPR119ALOX5APFEN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119095849-A | Macrocyclic heterocycles and uses thereof | 金橘生物科技公司 | 2024-12-06 | — | — | CN | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | DPP4 3640/4885GPR119 3709/4885KDM4E 3481/4885 |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | DPP4 3640/4885GPR119 3709/4885KDM4E 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.